Applied DNA COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models
Applied DNA Sciences, Inc. (APDN)
Last applied dna sciences, inc. earnings: 8/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adnas.com/molecular-based-security/investors
Company Research
Source: Business Wire
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA”) today announced that its COVID-19 collaboration partner, Takis Biotech, a Rome, Italy-based a company focused on the development of cancer vaccines founded by scientists from Merck Research Laboratories, has received approval from the Italy’s Ministry of Health to begin a pre-clinical trial of a COVID-19 vaccine candidate. As announced by Applied DNA on March 2, 2020, the vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA. Applied DNA entered large-scale production of the candidates in March 2020. Takis Biotech anticipates first results of its pre-clinical trial will be available in April 2020.Click here to read Takis Biotech’s announcement (in English and Italian): http://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-annou
Show less
Read more
Impact Snapshot
Event Time:
APDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APDN alerts
High impacting Applied DNA Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
APDN
News
- Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA [Yahoo! Finance]Yahoo! Finance
- Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA Accesswire
- Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines [Yahoo! Finance]Yahoo! Finance
- Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines Accesswire
APDN
Earnings
- 12/17/24 - Beat
APDN
Sec Filings
- 12/17/24 - Form 10-K
- 12/17/24 - Form 8-K
- 12/10/24 - Form DEFA14A
- APDN's page on the SEC website